BRCA1-associated breast cancers are mostly basal-like high-grade ductal carcinomas that frequently overexpress epidermal growth factor receptor (EGFR). Aberrant EGFR expression is correlated with disease progression, resistance to radiation and chemotherapy, and poor clinical prognosis. While BRCA1 is involved in multiple cellular processes, its functional role in EGFR regulation remains enigmatic. Here, we report a previously unrecognized post-transcriptional mechanism by which BRCA1 regulates EGFR expression through the induction of miR-146a. We demonstrate that EGFR expression correlates negatively with BRCA1, while miR-146a levels increase with BRCA1. We show that BRCA1 binds to miR-146a promoter and activates transcription, which in turn attenuates EGFR expression. Knockdown of miR-146a in BRCA1-overexpressing cells negated this effect and suppressed its ability to inhibit proliferation and transformation. In archived triple negative breast cancer (TNBC) samples, we show a strong positive correlation between BRCA1 and miR-146a expression. We also show that low expression of miR-146a strongly predicts positive lymph node status and is associated with distinctively poor overall survival of patients. Together, these observations provide insight into a novel BRCA1→miR-146a→EGFR paradigm by which BRCA1 carries out an aspect of tumor suppressor function that is potentially amenable to therapeutic intervention.
Germline mutations in the tumor suppressor BRCA1 (breast cancer 1, early onset) are associated with a substantially higher risk of developing basal-like breast cancer (BLBC). Many sporadic breast cancers express decreased levels of BRCA1 and show a strong resemblance to BRCA1-hereditary tumors. BRCA1-associated tumors are triple-negative (TN), basal-like high grade ductal carcinomas that display an undifferentiated phenotype and frequently overexpress epidermal growth factor receptor (EGFR/ERBB1/HER1) and basal cytokeratins (CK5, CK6, CK14 and CK17) and confer a poor clinical prognosis. Although upregulation of EGFR is commonly observed in BRCA1-associated breast cancer, the mechanism of EGFR regulation by BRCA1 is not understood. EGFR upregulation could occur at multiple transcriptional and/or post-transcriptional levels. MicroRNAs (miRNAs) are an evolutionarily conserved class of small non-coding RNAs that regulate gene expression post-transcriptionally and/or translationally. Several miRNAs are found to be differentially expressed in breast cancer and studies show their involvement in stem cell differentiation, epithelial-to-mesenchymal transition (EMT), invasion and metastasis. Identifying the functional relationship between loss of BRCA1 and miRNAs will help us understand the post-transcriptional mechanism by which BRCA1 deficiency leads to aberrant EGFR expression. In the current study, we show for the first time, a direct inverse correlation between BRCA1 and EGFR protein expression levels in breast cancer cell lines representing the different intrinsic subtypes and in primary mammary epithelial cells. By overexpression and knockdown of BRCA1, we demonstrate that BRCA1 loss results in increased stability of EGFR protein. Using our in vitro system of immortalized primary mammary epithelial cells, we evaluated the effect of functional loss of BRCA1 on the expression of miRNAs in secondary mammospheres which are enriched for stem-like cells and in cells differentiated in vitro. We observed that BRCA1 deficiency leads to dysregulation of miRNAs linked to stem cell renewal, EGFR signaling and EMT. miRNA gain-of-function experiments using Pre-miR™ miRNA precursors and loss-of-function experiments using miRCURY LNA™ miRNA inhibitors were performed with the selected miRNAs to further confirm their effect on EGFR expression. Results suggest that miRNA mediated EGFR deregulation could be a critical step in tumor initiation and progression in BRCA1 deficiency. Since EGFR upregulation is an early event in breast cancer, additional functional studies will provide a novel molecular mechanism by which BRCA1 deficiency leads to the development of BLBC with aberrant EGFR expression mediated by miRNAs. The study will offer new therapeutic approaches for BLBC, a highly aggressive disease with limited therapeutic options. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1188. doi:10.1158/1538-7445.AM2011-1188
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.